A New and Innovative Method for CO2 Removal in Anesthetic Circuits (memsorb)

February 4, 2026 updated by: DMF Medical Incorporated

A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate

The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia.

memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction.

This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit.

memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.

Study Type

Interventional

Enrollment (Actual)

286

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 3A7
        • Queen Elizabeth II HSC, Halifax Infirmary Site
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
  • English-speaking patients

Exclusion Criteria:

  • Self-reported as pregnant
  • American Society of Anesthesiologists Physical Status Class IV (high risk patient)
  • Patients scheduled for emergency surgery
  • Documented respiratory disease, including COPD and severe asthma
  • Documented elevated pressure in the brain (intra cranial pressure, ICP)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
Experimental: memsorb
Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Device: memsorb
memsorb is a CO2 filter replacing current chemical CO2 absorbers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
End-tidal CO2 Concentration (%)
Time Frame: From the start to the end of the intra-operative period for each participant
The mean concentration of carbon dioxide during the expiratory cycle, measured as a percentage (%), measured over the course of the surgical procedure.
From the start to the end of the intra-operative period for each participant

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fraction of Anaesthetic Agent (%)
Time Frame: From the start to the end of the intra-operative period for each participant
Inhaled and exhaled fraction of anaesthetic agent as collected from the anaesthetic patient record database. Mean % inhalational anesthetic was calculated per surgical procedure. Those means were used to calculate the overall mean
From the start to the end of the intra-operative period for each participant

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

DMF Medical Incorporated

Investigators

  • Principal Investigator: Orlando Hung, MD, Nova Scotia Health Authority

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2017

Primary Completion (Actual)

May 10, 2022

Study Completion (Actual)

July 24, 2024

Study Registration Dates

First Submitted

October 12, 2016

First Submitted That Met QC Criteria

January 5, 2017

First Posted (Estimated)

January 9, 2017

Study Record Updates

Last Update Posted (Actual)

February 23, 2026

Last Update Submitted That Met QC Criteria

February 4, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • DMF-CLIN-16-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anesthesia

Clinical Trials on memsorb

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe